T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1151
Skyworks Solutions
SWKS
$10.5B
| $13.6M | ﹤0.01% |
215,099
+1,846
| +0.9% | +$129K |
|
1152
Arcosa
ACA
$7.12B
| $13.6M | ﹤0.01% |
128,197
+81,103
| +172% | +$8.19M |
|
1153
Berkshire Hathaway Class A
BRK.A
$1.09T
| $13.6M | ﹤0.01% |
18
| – | – |
|
1154
Check Point Software Technologies
CHKP
$13.7B
| $13.6M | ﹤0.01% |
73,169
+3,583
| +5% | +$693K |
|
|
HSAI
1155
Hesai Group
HSAI
$3.03B
| $13.6M | ﹤0.01% |
606,060
| – | – |
|
1156
Hancock Whitney
HWC
$6.34B
| $13.5M | ﹤0.01% |
212,214
+16,153
| +8% | +$981K |
|
1157
Hamilton Lane
HLNE
$5.69B
| $13.5M | ﹤0.01% |
100,379
+53,987
| +116% | +$6.79M |
|
1158
Rivian
RIVN
$22.9B
| $13.4M | ﹤0.01% |
682,012
+38,177
| +6% | +$606K |
|
|
ZBIO
1159
Zenas BioPharma
ZBIO
$1.98B
| $13.4M | ﹤0.01% |
369,248
-5,050
| -1% | -$166K |
|
1160
Rithm Capital
RITM
$5.79B
| $13.4M | ﹤0.01% |
1,229,550
-230,712
| -16% | -$2.55M |
|
1161
Semtech
SMTC
$12.4B
| $13.4M | ﹤0.01% |
181,864
+3,661
| +2% | +$260K |
|
|
EVMN
1162
Evommune Inc
EVMN
$511M
| $13.4M | ﹤0.01% |
+782,121
| New | +$14.7M |
|
1163
Corcept Therapeutics
CORT
$12.1B
| $13.4M | ﹤0.01% |
384,246
+1,186
| +0.3% | +$93.2K |
|
1164
Pitney Bowes
PBI
$2.28B
| $13.3M | ﹤0.01% |
1,262,095
-827,252
| -40% | -$8.58M |
|
1165
Immuneering
IMRX
$336M
| $13.1M | ﹤0.01% |
1,993,958
+195,176
| +11% | +$1.25M |
|
1166
Fox Class B
FOX
$24.4B
| $13.1M | ﹤0.01% |
201,728
-964
| -0.5% | -$56.3K |
|
|
TEM
1167
Tempus AI
TEM
$9.8B
| $12.9M | ﹤0.01% |
217,910
-397,804
| -65% | -$31.1M |
|
|
NP
1168
Neptune Insurance Holdings
NP
$4.4B
| $12.8M | ﹤0.01% |
+440,523
| New | +$11.6M |
|
1169
Amdocs
DOX
$6.08B
| $12.8M | ﹤0.01% |
158,444
-18,491
| -10% | -$1.49M |
|
1170
Autoliv
ALV
$8.89B
| $12.7M | ﹤0.01% |
107,244
+11,213
| +12% | +$1.34M |
|
1171
Euronet Worldwide
EEFT
$2.78B
| $12.7M | ﹤0.01% |
166,427
+1,570
| +1% | +$122K |
|
1172
MoonLake Immunotherapeutics
MLTX
$1.4B
| $12.6M | ﹤0.01% |
959,553
+136,596
| +17% | +$1.61M |
|
1173
Carlyle Group
CG
$17.2B
| $12.5M | ﹤0.01% |
212,114
+9,396
| +5% | +$534K |
|
1174
Sanmina
SANM
$11.2B
| $12.5M | ﹤0.01% |
83,194
+32,352
| +64% | +$4.78M |
|
1175
Gates Industrial Corporation Ltd.
GTES
$7.05B
| $12.4M | ﹤0.01% |
578,749
+93,971
| +19% | +$2.17M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.